Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia.

[1][2][3] It is a non-peptide small‐molecule thrombopoietin receptor agonist.

[4] In China, it is approved for second-line treatment for primary immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA) in adults.

[4] This drug article relating to the blood and blood forming organs is a stub.

You can help Wikipedia by expanding it.